有斑点 发表于 2025-3-25 03:44:38

http://reply.papertrans.cn/23/2281/228051/228051_21.png

污点 发表于 2025-3-25 07:35:58

https://doi.org/10.1007/BFb0074253t in determining who may derive the most benefit from HSCT, as well as the optimal timing of such an intervention. Meanwhile, advances in the development of alternative donor sources and reduced-intensity conditioning regimens have expanded its potential application.

HAVOC 发表于 2025-3-25 11:56:49

http://reply.papertrans.cn/23/2281/228051/228051_23.png

Malleable 发表于 2025-3-25 16:40:26

http://reply.papertrans.cn/23/2281/228051/228051_24.png

Horizon 发表于 2025-3-25 21:14:33

Late Effects of Therapy of Acute Lymphoblastic Leukemiaon capture and reporting of even the most severe late effects, thus hampering meaningful comparisons of these across contemporary ALL protocols. This chapter summarizes the most prevalent late effects among ALL survivors and recent advances in mapping of these and outlines strategies for future research.

graphy 发表于 2025-3-26 00:58:48

http://reply.papertrans.cn/23/2281/228051/228051_26.png

FIR 发表于 2025-3-26 08:02:43

http://reply.papertrans.cn/23/2281/228051/228051_27.png

揉杂 发表于 2025-3-26 11:51:36

http://reply.papertrans.cn/23/2281/228051/228051_28.png

遣返回国 发表于 2025-3-26 13:07:51

http://reply.papertrans.cn/23/2281/228051/228051_29.png

Insul岛 发表于 2025-3-26 20:49:44

Genetic Mechanisms in T-Cell Acute Lymphoblastic LeukemiaMAPK, and PI3K signaling. In addition, aberrant expression of oncogenic transcription factors such as TAL1, LMO2, TLX1, and TLX3 and mutations in transcription factor tumor suppressors and epigenetic regulators result in altered differentiation and increased self-renewal.
页: 1 2 [3] 4 5 6
查看完整版本: Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz